A Study To Evaluate MYK-491 To Treat Patients With Primary Dilated Cardiomyopathy (DCM) Due To Genetic Variants

Overview

About this study

The purpose of this study is to establish safety and preliminary effectiveness of treatment with MYK-491 in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants .

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Has stable primary dilated cardiomyopathy due to either MYH7 or TTN variant.
  • Has adequate acoustic windows for echocardiography.
  • Maximum of 3 family members with same variant can be enrolled.

Exclusion Criteria:

  • Any significant structural cardiac abnormalities on Screening transthoracic echo(s).
  • A pathogenic variant implicated in DCM of another gene other than MYH7 or TTN.
  • Routinely scheduled outpatient intravenous (IV) infusions for heart failure (e.g., inotropes, vasodilators [e.g., nesiritide], diuretics), or routinely scheduled ultrafiltration.
  • Presence of protocol specified laboratory abnormalities at Screening.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Naveen Pereira, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions